Purpose/Objective

At the conclusion of the American Headache Society’s 2025 Scottsdale Headache Symposium, participants will be able to apply knowledge of the diagnosis, epidemiology, and treatment of primary headache disorders in adults and children in clinical practice and research, evaluate emerging clinical trial data and pipeline therapies to inform evidence-based treatment decisions for migraine, optimize patient outcomes with focused history-taking and effective communication strategies including motivational interviewing, and assess the real-world data for the efficacy and safety of neuromodulation therapies for primary headache disorders.

Accreditation Statement

The American Headache Society® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The American Headache Society® designates this Live activity for a maximum of 21.25  AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Headache Society® designates this enduring material (recorded sessions) for a maximum of 35.25  AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Recorded sessions will be available via Education On Demand beginning Tuesday, December 23, 2025 through Tuesday, June 23, 2026. Pre-courses will be available separately.

AAFP

The AAFP has reviewed 2025 Scottsdale Headache Symposium and deemed it acceptable for up to 21.00 Live AAFP Elective credit(s). Term of Approval is from 12/4/2025 to 12/7/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPN

THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY HAS REVIEWED THE 2025 SCOTTSDALE HEADACHE SYMPOSIUM AND HAS APPROVED THIS ACTIVITY AS PART OF A COMPREHENSIVE SELF-ASSESSMENT (SA) CME ACTIVITY, WHICH IS MANDATED BY THE ABMS AS A NECESSARY COMPONENT OF CONTINUING CERTIFICATION.

This activity awards up to 21.00  Category 1 CME which are approved as Self-Assessment credits. The approval period is for December 4-7, 2025.

Pharmacology

This content has been reviewed for pharmacology hours and the calculated value is: 16.25 hours of pharmacology content.

Instructions for Claiming CME

1. Complete the post-activity evaluation via Education On Demand.
   1. Login/create a new visitor account (when creating an account, please be sure to use the email address you used during registration).
2. For ABPN Self-Assessment Credit, complete the short ABPN Self-Assessment Quiz.
3. Enter the number of CME credits being claimed* per credit type.
4. Download your certificate. Certificates will only be issued for AMA PRA Category 1 Credit™ (MDs/DOs) or Participation credit (all others).

*Please note: The maximum number of credits is calculated based on attending all live and/or watching all recorded concurrent sessions. View CME hours per session on the program here.

Financial Disclosures

The planners and faculty for this activity did not have any relationships to disclose unless listed here. All relevant relationships were mitigated prior to the start of the activity according to ACCME Standards.

Disclosure of Commercial Support

The American Headache Society® received funding for this activity from the following organizations:

AbbVie Inc.
Axsome Therapeutics
Lundbeck LLC.
Pfizer Inc.

The American Headache Society received an in-kind donation of migraine units (heads) for the Injection Training Workshop from the following organizations:

AbbVie Inc.